

ERRATUM

Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’



[ESMO Open Volume 7, Issue 2, April 2022, 100447]

S. Ochsenreither^{1,2,3*}, W. M. Fiedler⁴, G. Del Conte⁵, M. Macchini⁵, I. Matos⁶, B. Habel⁷, I. Ahrens-Fath⁷, F. Raspagliesi⁸, D. Lorusso⁸, U. Keilholz^{1,3,9}, C. Rolling⁴, M. Kebenko⁴, K. F. Klinghammer^{1,2}, O. Saavedra⁶, H. Baumeister⁷, A. Zurlo⁷ & A. Garralda⁵

¹Charité Comprehensive Cancer Center, Berlin; ²Charité, Department of Hematology, Oncology and Tumor Immunology, Berlin; ³German Cancer Consortium (DKTK), Berlin; ⁴University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany; ⁵Fondazione IRCCS San Raffaele Hospital, Milan, Italy; ⁶Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; ⁷Glycotope GmbH, Berlin, Germany; ⁸Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁹Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany

The publisher regrets that the authorship list was incorrectly published, the corrected list is above.

The publisher would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.esmoop.2022.100447>

*Correspondence to: S. Ochsenreither

E-mail: sebastian.ochsenreither@charite.de (S. Ochsenreither).

2059-7029/© 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. All rights reserved.